Temporal analysis of 4464 patients from 61 studies demonstrated significant survival improvements post-2020 (log-rank p < 0.0001).<h4>Conclusions</h4>This study establishes the first real-world unadjusted survival reference for subtypes in breast cancer spinal metastases, suggesting a potential survival advantage of HER2 + /HR + over HER2 + /HR - tumors. Here, ERBB2 is linked to breast carcinoma.